7 results about "Chlamydia" patented technology

The present application belongs to the field of molecular biology detection, and particularly relates to a composition, method and use for simultaneous detection and differentiation of swine fever virus, psittacosis chlamydia, porcine reproductive and respiratory syndrome virus and porcine circovirus type II. The composition for simultaneous detection provided by the present application can realize rapid detection of four pathogen target genes in one tube of reaction solution by using multiplex fluorescence RPA detection technology, and has the advantages of high throughput, short time and low cost. On one hand, the present application can accurately detect pathogens and analyze mixed infection of pathogens, so as to achieve the effect of precise medication, reduce the use of antibiotics, save costs, and reduce the cost and increase the benefit of enterprises, and on the other hand, compared with fluorescence PCR, the detection time is greatly shortened, and the purpose of rapid detection is achieved.

The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

Provided is the determination of the three-dimensional structure of Chlamydia major outer membrane protein and applications and uses thereof, including for vaccine development, drug development, and diagnostics.

The present application relates to the technical field of biological detection, in particular to a composition and application thereof. The present application provides a composition and application thereof in a process of coating a magnetic bead with a natural antigen of Chlamydia pneumoniae, and a Chlamydia pneumoniae IgG antibody detection kit (magnetic microparticle chemiluminescence method). In the process, a surfactant and a reducing agent are added in the antigen coating process to improve the contrast of the detection results, a heat sealing process for 3 days is adopted to reduce the result range between different samples, and CB alkaline buffer is used as a sealing liquid buffer to improve the aggregation problem of the magnetic beads.

Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., demodex), worms, protozoa (e.g., amoeba (e.g., acanthamoeba or cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. Said compositions and methods comprise compounds which demonstrate immunological, keratolytic, anti-histamine, anti-inflammatory, and / or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

The application discloses a cervical cancer plasma circulating microbial marker combination, a reagent, a kit, a risk assessment model and application thereof, and belongs to the technical field of liquid biopsy and microbiome. The cervical cancer plasma circulating microbial marker combination comprises Prevotella, Sneathia, Chlamydia trachomatis, Peptostreptococcus, Fusobacterium, Campylobacter and Haemophilus. The cervical cancer plasma circulating microbial marker combination is used for verifying cervical cancer patients and healthy people, and the AUC value is 0.939, the sensitivity is 81.58%, the specificity is 90.00%, the accuracy is 85.29%, the positive predictive value is 91.18%, and the negative predictive value is 79.41%, which indicates that the cervical cancer plasma circulating microbial marker combination can effectively distinguish cervical cancer patients from healthy people, is suitable for early screening of cervical cancer, and has significant clinical screening application value.